SCHEMBL22494766

SCHEMBL22494766

CC(C)(C)c1cnc(NC(=O)[C@H]2CC[C@@H](NC#N)C2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.47
CNR2 P34972 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
CDK2 P24941 14/20 0.41
CCNE2 O96020 4/20 0.41
CCNE1 P24864 4/20 0.41
CDK9 P50750 12/20 0.41
LCK P06239 1/20 0.39
CDK7 P50613 3/20 0.39
CCNT1 O60563 2/20 0.39
CDK1 P06493 2/20 0.39
CCNB1 P14635 2/20 0.39
CCNH P51946 2/20 0.39
CIT O14578 1/20 0.39
CASK O14936 1/20 0.39
AURKA O14965 1/20 0.39
GAK O14976 1/20 0.39
DCLK1 O15075 1/20 0.39
MAP3K7 O43318 1/20 0.39
ULK1 O75385 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22494687 0.91 CNR2 (0.45) RAB9ACNR2SMN1; SMN2CDK2CCNE2
SCHEMBL22494688 0.91 CNR2 (0.45) RAB9ACNR2SMN1; SMN2CDK2CCNE2
SCHEMBL22494694 0.91 CNR2 (0.45) RAB9ACNR2SMN1; SMN2CDK2CCNE2
SCHEMBL12851970 0.85 RAB9A (0.62) RAB9ACNR2SMN1; SMN2CDK2CCNE2
SCHEMBL24514543 0.80 CCNE1 (0.48) RAB9ASMN1; SMN2CDK2CCNE1CDK5
SCHEMBL22494774 0.80 CCNE1 (0.48) RAB9ASMN1; SMN2CDK2CCNE1CDK5
SCHEMBL20883072 0.78 UCHL1 (0.62) CNR2CDK2CCNE1CDK5MKNK1
SCHEMBL20883082 0.78 UCHL1 (0.44) RAB9ACNR2SMN1; SMN2CDK2CCNE1
SCHEMBL22494806 0.78 UCHL1 (0.62) CNR2CDK2CCNE1CDK5MKNK1
SCHEMBL20883074 0.78 UCHL1 (0.62) CNR2CDK2CCNE1CDK5MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 EP claimed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 US claimed
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 EP disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 US disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 RAB9A 1612/4885CNR2 4763/4885SMN1; SMN2 88/4885
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 USP30, UCHL1, UCHL3 RAB9A 1020/4885CNR2 4587/4885SMN1; SMN2 181/4885
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 RAB9A 1612/4885CNR2 4763/4885SMN1; SMN2 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.